+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Innoviva Inc (INVA) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 47 Pages
  • April 2023
  • GlobalData
  • ID: 4281502
Innoviva Inc (INVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Innoviva Inc (Innoviva) is a company with a portfolio of royalties. It partners with companies that advance innovative therapies for improving patient care and building long-lasting value. Its operations primarily focus on royalty management. The company has partnership agreements with GSK for commercialization and development of respiratory products. Its current portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK) for various respiratory disorders. The company's R&D also focuses on developing innovative formulations for the treatment of respiratory disorders. It receives royalty payments on the sale of these partnered products to clients as per the terms of its agreements with GSK. Innoviva is headquartered in Brisbane, California, the US.

Innoviva Inc Key Recent Developments

  • Nov 09, 2022: Innoviva Reports Third Quarter 2022 Financial Results
  • Sep 08, 2022: Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
  • Jul 14, 2022: Innoviva agrees to sell stake in Theravance Respiratory Company
  • Jul 11, 2022: Innoviva enters agreement to acquire La Jolla Pharmaceutical Company

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Innoviva Inc - Key Facts
  • Innoviva Inc - Key Employees
  • Innoviva Inc - Key Employee Biographies
  • Innoviva Inc - Major Products and Services
  • Innoviva Inc - History
  • Innoviva Inc - Company Statement
  • Innoviva Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Innoviva Inc - Business Description
  • Product Category: ANORO
  • Performance
  • Product Category: RELVAR/BREO
  • Performance
  • Product Category: TRELEGY
  • Performance
  • Innoviva Inc - Corporate Strategy
  • Innoviva Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Innoviva Inc - Strengths
  • Innoviva Inc - Weaknesses
  • Innoviva Inc - Opportunities
  • Innoviva Inc - Threats
  • Innoviva Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Innoviva Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 09, 2022: Innoviva Reports Third Quarter 2022 Financial Results
  • Sep 08, 2022: Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
  • Jul 14, 2022: Innoviva agrees to sell stake in Theravance Respiratory Company
  • Jul 11, 2022: Innoviva enters agreement to acquire La Jolla Pharmaceutical Company
  • Jul 08, 2022: Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc
  • May 24, 2022: Innoviva enters agreement to acquire biopharma firm Entasis
  • Apr 27, 2022: Innoviva Reports First Quarter 2022 Financial Results
  • Feb 09, 2022: Innoviva Reports Fourth Quarter 2021 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Innoviva Inc, Key Facts
  • Innoviva Inc, Key Employees
  • Innoviva Inc, Key Employee Biographies
  • Innoviva Inc, Major Products and Services
  • Innoviva Inc, History
  • Innoviva Inc, Subsidiaries
  • Innoviva Inc, Key Competitors
  • Innoviva Inc, Ratios based on current share price
  • Innoviva Inc, Annual Ratios
  • Innoviva Inc, Interim Ratios
  • Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Innoviva Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Innoviva Inc, Performance Chart (2018 - 2022)
  • Innoviva Inc, Ratio Charts
  • Innoviva Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Innoviva Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Teva Pharmaceuticals USA Inc
  • Titan Pharmaceuticals Inc
  • Novartis Corp
  • Sunovion Pharmaceuticals Inc
  • AstraZeneca Pharmaceuticals LP
  • GSK plc
  • Genentech USA Inc
  • Viatris Inc
  • Merck & Co Inc
  • Boehringer Ingelheim Corp
  • Chiesi USA Inc
  • GSK plc
  • Genentech USA Inc
  • Titan Pharmaceuticals Inc
  • Novartis Corp
  • Chiesi USA Inc
  • Viatris Inc
  • Merck & Co Inc
  • Teva Pharmaceuticals USA Inc
  • Sunovion Pharmaceuticals Inc
  • AstraZeneca Pharmaceuticals LP
  • Boehringer Ingelheim Corp